{
  "symbol": "AMGN",
  "year": 2024,
  "period": "Q2",
  "competition_summary": [
    {
      "competitor": "Litigation Amgen Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "al. v. Celltrion Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Amgen Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Amgen Manufacturing Limited LLC",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Celltrion Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Celltrion USA, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Celltrion",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "FDA",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "a Biologics License Application",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Amgen",
      "mentions": 10,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Asserted",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "the New Jersey District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "ABP",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Regeneron Pharmaceuticals, Inc.",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Regeneron",
      "mentions": 5,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "the U.S. District Court",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Sensipar (Sensipar Plaintiffs",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "The U.S. Court of Appeals",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "the Third Circuit",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "the Sensipar Plaintiffs",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Sensipar Plaintiffs",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "U.S. Tax Litigation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Related Matters Amgen Inc. & Subsidiaries",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "IRS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "Company",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "the U.S. Tax Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "ChemoCentryx, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "the United States Court of Appeals",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "ChemoCentryx",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "RA Capital Healthcare Fund",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "the California Superior Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "ANALYSIS OF FINANCIAL CONDITION",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "MD&A",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "SEC",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    },
    {
      "competitor": "EPS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Celltrion Inc., et al. On May 28, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Celltrion Inc. and Celltrion USA, Inc. (collectively, Celltrion) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA produc"
    }
  ]
}